董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ornella Barra | 女 | Director | 70 | 未披露 | 3049.00 | 2024-10-01 |
| Lorence H. Kim | 男 | Director | 50 | 39.73万美元 | 未持股 | 2024-10-01 |
| Dennis M. Nally | 男 | Director | 71 | 37.54万美元 | 0.51 | 2024-10-01 |
| Redonda G. Miller | 女 | Director | 57 | 31.18万美元 | 未持股 | 2024-10-01 |
| Werner Baumann | 男 | Director | 61 | 未披露 | 未持股 | 2024-10-01 |
| Lauren Tyler | 女 | Director | 62 | 未披露 | 未持股 | 2024-10-01 |
| D. Mark Durcan | 男 | Lead Independent Director | 63 | 38.01万美元 | 1.43 | 2024-10-01 |
| Richard W. Gochnauer | 男 | Director | 74 | 30.01万美元 | 2.08 | 2024-10-01 |
| Steven H. Collis | 男 | Executive Chairman | 62 | 1751.12万美元 | 63.67 | 2024-10-01 |
| Lon R. Greenberg | 男 | Director | 74 | 33.26万美元 | 1.66 | 2024-10-01 |
| Kathleen Hyle | 女 | Director | 65 | 32.01万美元 | 1.78 | 2024-10-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert P. Mauch | 男 | President and Chief Executive Officer | 57 | 769.79万美元 | 12.71 | 2024-10-01 |
| Gina K. Clark | 女 | Executive Vice President and Chief Communications & Administration Officer | 67 | 317.02万美元 | 5.30 | 2024-10-01 |
| Lazarus Krikorian | -- | Senior Vice President and Chief Accounting Officer | -- | 未披露 | 未持股 | 2024-10-01 |
| Silvana Battaglia | 女 | Executive Vice President and Chief Human Resources Officer | 57 | 347.98万美元 | 未持股 | 2024-10-01 |
| Leslie E. Donato | 女 | Executive Vice President and Chief Strategy Officer | 55 | 未披露 | 未持股 | 2024-10-01 |
| Elizabeth S. Campbell | 女 | Executive Vice President and Chief Legal Officer | 50 | 402.72万美元 | 2.03 | 2024-10-01 |
| James F. Cleary, Jr. | 男 | Executive Vice President and Chief Financial Officer | 61 | 544.94万美元 | 19.31 | 2024-10-01 |
| Steven H. Collis | 男 | Executive Chairman | 62 | 1751.12万美元 | 63.67 | 2024-10-01 |
董事简历
中英对照 | 中文 | 英文- Ornella Barra
-
Ornella Barra是Walgreens Boots Alliance, Inc.的执行副总裁；是全球批发与国际零售部的总裁兼首席执行官；从2013年9月到2015年1月，担任Alliance Boots GmbH的批发与品牌部的首席执行官；从2009年1月到2013年9月，担任Alliance Boots GmbH的药物批发部门的首席执行官。担任药物批发部门的首席执行官前，Barra女士担任批发与商务事务部总监，并是Alliance Boots plc的董事；Alliance UniChem Plc与Boots Group plc合并前，Barra女士担任Alliance UniChem Plc的执行董事，Alliance Sante与UniChem Plc于1997年合并时即被任命为其董事；从2013年4月开始担任意大利最大的保险公司之一Assicurazioni Generali的董事；Barra女士从2007年6月开始一直担任Walgreens Boots Alliance的子公司Alliance Boots GmbH的董事；从2009年到2013年，担任其公司社会责任委员会（Corporate Social Responsibility Committee）的主席。
Ornella Barra,has served on Cencora, Inc. Board since January 2015. She currently serves as Chief Operating Officer, International of Walgreens Boots Alliance, Inc. Previously, she served as Co-Chief Operating Officer of Walgreens Boots Alliance, Inc. from June 2016 until April 2021. Ms. Barra served as Executive Vice President of Walgreens Boots Alliance, Inc. and President and Chief Executive of Global Wholesale and International Retail from February 2015 until June 2016. Ms. Barra served as Chief Executive, Wholesale and Brands of Alliance Boots GmbH from September 2013 until January 2015 and as Chief Executive of the Pharmaceutical Wholesale Division of Alliance Boots GmbH from January 2009 until September 2013. Prior to her role as Chief Executive of the Pharmaceutical Wholesale Division, Ms. Barra was the Wholesale and Commercial Affairs Director and a Board member of Alliance Boots plc. Prior to the merger of Alliance UniChem Plc and Boots Group plc, Ms. Barra served on the Board of Alliance Participations Limited. Ms. Barra is an honorary Professor of the University of Nottingham's School of Pharmacy and is a member of the Advisory Council of SDA School of Management, Bocconi University. Ms. Barra was formerly a member of the Board of Directors of Assicurazioni Generali S.p.A., one of the largest Italian insurance companies, from April 2013 to April 2019. Ms. Barra was a member of the Board of Directors of Alliance Boots GmbH between June 2007 and February 2015, and was Chair of its Corporate Social Responsibility Committee from 2009 to 2014. She serves as a member of the Board of International Federation of Pharmaceutical Wholesalers, Inc. - Ornella Barra是Walgreens Boots Alliance, Inc.的执行副总裁；是全球批发与国际零售部的总裁兼首席执行官；从2013年9月到2015年1月，担任Alliance Boots GmbH的批发与品牌部的首席执行官；从2009年1月到2013年9月，担任Alliance Boots GmbH的药物批发部门的首席执行官。担任药物批发部门的首席执行官前，Barra女士担任批发与商务事务部总监，并是Alliance Boots plc的董事；Alliance UniChem Plc与Boots Group plc合并前，Barra女士担任Alliance UniChem Plc的执行董事，Alliance Sante与UniChem Plc于1997年合并时即被任命为其董事；从2013年4月开始担任意大利最大的保险公司之一Assicurazioni Generali的董事；Barra女士从2007年6月开始一直担任Walgreens Boots Alliance的子公司Alliance Boots GmbH的董事；从2009年到2013年，担任其公司社会责任委员会（Corporate Social Responsibility Committee）的主席。
- Ornella Barra,has served on Cencora, Inc. Board since January 2015. She currently serves as Chief Operating Officer, International of Walgreens Boots Alliance, Inc. Previously, she served as Co-Chief Operating Officer of Walgreens Boots Alliance, Inc. from June 2016 until April 2021. Ms. Barra served as Executive Vice President of Walgreens Boots Alliance, Inc. and President and Chief Executive of Global Wholesale and International Retail from February 2015 until June 2016. Ms. Barra served as Chief Executive, Wholesale and Brands of Alliance Boots GmbH from September 2013 until January 2015 and as Chief Executive of the Pharmaceutical Wholesale Division of Alliance Boots GmbH from January 2009 until September 2013. Prior to her role as Chief Executive of the Pharmaceutical Wholesale Division, Ms. Barra was the Wholesale and Commercial Affairs Director and a Board member of Alliance Boots plc. Prior to the merger of Alliance UniChem Plc and Boots Group plc, Ms. Barra served on the Board of Alliance Participations Limited. Ms. Barra is an honorary Professor of the University of Nottingham's School of Pharmacy and is a member of the Advisory Council of SDA School of Management, Bocconi University. Ms. Barra was formerly a member of the Board of Directors of Assicurazioni Generali S.p.A., one of the largest Italian insurance companies, from April 2013 to April 2019. Ms. Barra was a member of the Board of Directors of Alliance Boots GmbH between June 2007 and February 2015, and was Chair of its Corporate Social Responsibility Committee from 2009 to 2014. She serves as a member of the Board of International Federation of Pharmaceutical Wholesalers, Inc.
- Lorence H. Kim
-
Lorence H. Kim，2014年10月起担任本公司董事会成员。2014年4月起，在一家生物科技公司- Moderna Therapeutics担任财务总监。2000年7月-2014年4月，在一家投资银行- Goldman, Sachs & Co.担任许多职位，最近担任总经理和生物科技投资银行业务联席主管。他持有Harvard大学的学士学位、Pennsylvania大学Wharton学院的医疗管理工商管理硕士学位，以及Pennsylvania大学医学院的医学博士学位。
Lorence H. Kim,has served on Cencora, Inc. Board since October 2022 and currently is a Venture Partner at Ascenta Capital. He served as a Venture Partner at Third Rock Ventures from September 2020 to December 2022. He served as Chief Financial Officer of Moderna, Inc. from April 2014 to June 2020. From July 2000 to April 2014, Dr. Kim held a number of positions at Goldman, Sachs & Co., most recently as Managing Director and Co-Head, Biotechnology Investment Banking. Dr. Kim has served as a director of Revolution Medicines, Inc., since July 2022, and has served as a director of TD Cowen (formerly Cowen, Inc.) since February 2022. Dr. Kim is currently a member of the American Red Cross Board of Governors. He previously served as a member of the Board of Directors of Seres Therapeutics from October 2014 to June 2020. - Lorence H. Kim，2014年10月起担任本公司董事会成员。2014年4月起，在一家生物科技公司- Moderna Therapeutics担任财务总监。2000年7月-2014年4月，在一家投资银行- Goldman, Sachs & Co.担任许多职位，最近担任总经理和生物科技投资银行业务联席主管。他持有Harvard大学的学士学位、Pennsylvania大学Wharton学院的医疗管理工商管理硕士学位，以及Pennsylvania大学医学院的医学博士学位。
- Lorence H. Kim,has served on Cencora, Inc. Board since October 2022 and currently is a Venture Partner at Ascenta Capital. He served as a Venture Partner at Third Rock Ventures from September 2020 to December 2022. He served as Chief Financial Officer of Moderna, Inc. from April 2014 to June 2020. From July 2000 to April 2014, Dr. Kim held a number of positions at Goldman, Sachs & Co., most recently as Managing Director and Co-Head, Biotechnology Investment Banking. Dr. Kim has served as a director of Revolution Medicines, Inc., since July 2022, and has served as a director of TD Cowen (formerly Cowen, Inc.) since February 2022. Dr. Kim is currently a member of the American Red Cross Board of Governors. He previously served as a member of the Board of Directors of Seres Therapeutics from October 2014 to June 2020.
- Dennis M. Nally
-
Dennis M. Nally于2020年1月加入董事会。2009年至2016年，他担任普华永道网络协调与治理实体普华永道会计师事务所主席。2002年至2009年，他担任美国董事长兼高级合伙人。 普华永道会计师事务所。 他于1974年加入普华永道会计师事务所（PricewaterhouseCoopers LLP），并于1985年成为合伙人，在组织内担任多个领导职务，包括国家战略计划总监，审计和业务咨询服务负责人以及执行合伙人。 Nally先生是Morgan Stanley and Globality，Inc.的董事会成员。
Dennis M. Nally,Chair of PricewaterhouseCoopers International Ltd., the coordinating and governance entity of the PwC network, from 2009 to July 2016.Chair and Senior Partner of the U.S. firm of PwC from May 2002 to June 2009.Joined PwC in 1974 and became a partner in 1985, serving in numerous leadership positions within PwC, including National Director of Strategic Planning, Audit and Business Advisory Services Leader and Managing Partner.Western Michigan University, Bachelor's Degree. - Dennis M. Nally于2020年1月加入董事会。2009年至2016年，他担任普华永道网络协调与治理实体普华永道会计师事务所主席。2002年至2009年，他担任美国董事长兼高级合伙人。 普华永道会计师事务所。 他于1974年加入普华永道会计师事务所（PricewaterhouseCoopers LLP），并于1985年成为合伙人，在组织内担任多个领导职务，包括国家战略计划总监，审计和业务咨询服务负责人以及执行合伙人。 Nally先生是Morgan Stanley and Globality，Inc.的董事会成员。
- Dennis M. Nally,Chair of PricewaterhouseCoopers International Ltd., the coordinating and governance entity of the PwC network, from 2009 to July 2016.Chair and Senior Partner of the U.S. firm of PwC from May 2002 to June 2009.Joined PwC in 1974 and became a partner in 1985, serving in numerous leadership positions within PwC, including National Director of Strategic Planning, Audit and Business Advisory Services Leader and Managing Partner.Western Michigan University, Bachelor's Degree.
- Redonda G. Miller
-
Redonda G. Miller，自2023年1月起在Amerisourcebergen公司董事会任职。自2016年起，她担任The Johns Hopkins Hospital院长。2016年至2017年，Miller博士担任The Johns Hopkins Hospital和卫生系统首席医疗官兼医疗事务高级副总裁，2009年至2016年担任The Johns Hopkins Hospital和卫生系统首席医疗官兼医疗事务副总裁。自2006年以来，Miller博士一直是约翰霍普金斯大学医学系的副教授。2021年11月至2022年10月，她担任Invivyd公司（原Adagio Therapeutics, Inc.）的非执行董事。Miller博士是Gilchrist Hospice Care，Inc.的董事会成员和Turnaround Tuesday Inc.的董事会成员。
Redonda G. Miller,has served on Cencora, Inc. Board since January 2023. She has served as the President of The Johns Hopkins Hospital since 2016. Previously, Dr. Miller was Chief Medical Officer and Senior Vice President of Medical Affairs of The Johns Hopkins Hospital and Health System from 2016 to 2017, and Chief Medical Officer and Vice President of Medical Affairs of The Johns Hopkins Hospital and Health System from 2009 to 2016. Dr. Miller has been an associate professor in the Department of Medicine at The Johns Hopkins University since 2006. From November 2021 to October 2022, she was a non-executive director at Invivyd, Inc. (formerly Adagio Therapeutics, Inc.). Dr. Miller is a member of the Board of Directors of Gilchrist Hospice Care, Inc. and a member of the Board of Directors of Turnaround Tuesday Inc. - Redonda G. Miller，自2023年1月起在Amerisourcebergen公司董事会任职。自2016年起，她担任The Johns Hopkins Hospital院长。2016年至2017年，Miller博士担任The Johns Hopkins Hospital和卫生系统首席医疗官兼医疗事务高级副总裁，2009年至2016年担任The Johns Hopkins Hospital和卫生系统首席医疗官兼医疗事务副总裁。自2006年以来，Miller博士一直是约翰霍普金斯大学医学系的副教授。2021年11月至2022年10月，她担任Invivyd公司（原Adagio Therapeutics, Inc.）的非执行董事。Miller博士是Gilchrist Hospice Care，Inc.的董事会成员和Turnaround Tuesday Inc.的董事会成员。
- Redonda G. Miller,has served on Cencora, Inc. Board since January 2023. She has served as the President of The Johns Hopkins Hospital since 2016. Previously, Dr. Miller was Chief Medical Officer and Senior Vice President of Medical Affairs of The Johns Hopkins Hospital and Health System from 2016 to 2017, and Chief Medical Officer and Vice President of Medical Affairs of The Johns Hopkins Hospital and Health System from 2009 to 2016. Dr. Miller has been an associate professor in the Department of Medicine at The Johns Hopkins University since 2006. From November 2021 to October 2022, she was a non-executive director at Invivyd, Inc. (formerly Adagio Therapeutics, Inc.). Dr. Miller is a member of the Board of Directors of Gilchrist Hospice Care, Inc. and a member of the Board of Directors of Turnaround Tuesday Inc.
- Werner Baumann
-
Werner Baumann，自2016年5月起担任Bayer AG（一家在医疗保健和营养生命科学领域具有核心竞争力的全球企业）的首席执行官兼管理委员会主席，并自2020年1月起担任首席可持续发展官。Baumann先生于1988年加入Bayer，并在公司担任多个职位，包括从2010年到2014年担任首席财务官，从2014年到2016年担任首席战略和投资组合官。2010年至2016年，他还担任Bayer管理委员会的执行董事。他在科隆大学（University of Cologne）获得学士学位，在亚琛工业大学（RWTH Aachen University）获得硕士学位。
Werner Baumann,has served on Cencora, Inc. Board since October 2023. He previously served as Chief Executive Officer and Chairman of the Board of Management of Bayer AG from May 2016 until his retirement in May 2023, and as Chief Sustainability Officer from January 2020 to May 2023. Mr. Baumann joined Bayer AG in 1988 and held numerous positions of increasing responsibility at the company, including positions on the Board of Management of Bayer AG as Chief Financial Officer from 2010 to 2014 and Chief Strategy and Portfolio Officer from 2014 to 2016. - Werner Baumann，自2016年5月起担任Bayer AG（一家在医疗保健和营养生命科学领域具有核心竞争力的全球企业）的首席执行官兼管理委员会主席，并自2020年1月起担任首席可持续发展官。Baumann先生于1988年加入Bayer，并在公司担任多个职位，包括从2010年到2014年担任首席财务官，从2014年到2016年担任首席战略和投资组合官。2010年至2016年，他还担任Bayer管理委员会的执行董事。他在科隆大学（University of Cologne）获得学士学位，在亚琛工业大学（RWTH Aachen University）获得硕士学位。
- Werner Baumann,has served on Cencora, Inc. Board since October 2023. He previously served as Chief Executive Officer and Chairman of the Board of Management of Bayer AG from May 2016 until his retirement in May 2023, and as Chief Sustainability Officer from January 2020 to May 2023. Mr. Baumann joined Bayer AG in 1988 and held numerous positions of increasing responsibility at the company, including positions on the Board of Management of Bayer AG as Chief Financial Officer from 2010 to 2014 and Chief Strategy and Portfolio Officer from 2014 to 2016.
- Lauren Tyler
-
Lauren Tyler，自2015年起担任J.P. Morgan Asset & Wealth Management（投资管理领域的全球领导者）的执行副总裁兼全球人力资源主管。在此之前，她曾担任JPMorgan Chase & Co.的各种领导职务，包括全球首席审计师和投资者关系全球主管。泰勒女士是一位经验丰富的财务主管，在私募股权、投资银行和金融领域拥有35年的经验。Tyler女士此前从2019年1月起担任Alleghany Corporation的董事会成员，直到2022年10月被伯克希尔哈撒韦公司收购。泰勒女士获得耶鲁大学学士学位和哈佛大学工商管理硕士学位。
Lauren Tyler,has served on Cencora, Inc. Board since October 2023. Since 2015, she has served as Executive Vice President and Global Head of Human Resources at J.P. Morgan Asset & Wealth Management. Prior to this role, Ms. Tyler served in various leadership roles at JPMorgan Chase & Co., including as Global Chief Auditor and Global Head of Investor Relations. Ms. Tyler is a seasoned financial executive with 35 years of experience in private equity, investment banking and finance. Ms. Tyler previously served on the Board of Directors of Alleghany Corporation from January 2019 until its acquisition by Berkshire Hathaway in October 2022. - Lauren Tyler，自2015年起担任J.P. Morgan Asset & Wealth Management（投资管理领域的全球领导者）的执行副总裁兼全球人力资源主管。在此之前，她曾担任JPMorgan Chase & Co.的各种领导职务，包括全球首席审计师和投资者关系全球主管。泰勒女士是一位经验丰富的财务主管，在私募股权、投资银行和金融领域拥有35年的经验。Tyler女士此前从2019年1月起担任Alleghany Corporation的董事会成员，直到2022年10月被伯克希尔哈撒韦公司收购。泰勒女士获得耶鲁大学学士学位和哈佛大学工商管理硕士学位。
- Lauren Tyler,has served on Cencora, Inc. Board since October 2023. Since 2015, she has served as Executive Vice President and Global Head of Human Resources at J.P. Morgan Asset & Wealth Management. Prior to this role, Ms. Tyler served in various leadership roles at JPMorgan Chase & Co., including as Global Chief Auditor and Global Head of Investor Relations. Ms. Tyler is a seasoned financial executive with 35 years of experience in private equity, investment banking and finance. Ms. Tyler previously served on the Board of Directors of Alleghany Corporation from January 2019 until its acquisition by Berkshire Hathaway in October 2022.
- D. Mark Durcan
-
D. Mark Durcan于1984年6月加入公司，自那时起出任多个职位。 于2006年2月被任命为公司首席运营官，2007年6月成为总裁，2012年2月成为董事兼行政总裁。自1996年以来担任官员。D他在莱斯大学获得MCHE化学工程的学士学位。自2012年2月起担任公司董事会董事。
D. Mark Durcan,has served on Cencora, Inc. Board since September 2015 and as Lead Independent Director since March 2023. He served as Chief Executive Officer and Director of Micron Technology, Inc. from February 2012 until his retirement in May 2017. Mr. Durcan served as President and Chief Operating Officer of Micron Technology, Inc. from June 2007 to February 2012, as Chief Operating Officer from February 2006 to June 2007, and as Chief Technology Officer from June 1997 to February 2006. Between 1984 and February 2006, Mr. Durcan held various other positions with Micron Technology, Inc. and its subsidiaries and served as an officer from 1996 through his retirement. Mr. Durcan served as a director of MWI Veterinary Supply, Inc. from March 2014 until its acquisition by AmerisourceBergen in February 2015. Mr. Durcan has served as a director for Advanced Micro Devices since October 2017 and for ASML Holding NV since April 2020. He previously served as a director of Veoneer from April 2018 to April 2022 and served as a director at Freescale Semiconductor, Inc. from 2014 through 2015. Mr. Durcan has been a director for St. Luke's Health System of Idaho since February 2017 and has served on the Board of Trustees of Rice University since June 2020. He has also served on the Semiconductor Industry Association Board and the Technology CEO Council. - D. Mark Durcan于1984年6月加入公司，自那时起出任多个职位。 于2006年2月被任命为公司首席运营官，2007年6月成为总裁，2012年2月成为董事兼行政总裁。自1996年以来担任官员。D他在莱斯大学获得MCHE化学工程的学士学位。自2012年2月起担任公司董事会董事。
- D. Mark Durcan,has served on Cencora, Inc. Board since September 2015 and as Lead Independent Director since March 2023. He served as Chief Executive Officer and Director of Micron Technology, Inc. from February 2012 until his retirement in May 2017. Mr. Durcan served as President and Chief Operating Officer of Micron Technology, Inc. from June 2007 to February 2012, as Chief Operating Officer from February 2006 to June 2007, and as Chief Technology Officer from June 1997 to February 2006. Between 1984 and February 2006, Mr. Durcan held various other positions with Micron Technology, Inc. and its subsidiaries and served as an officer from 1996 through his retirement. Mr. Durcan served as a director of MWI Veterinary Supply, Inc. from March 2014 until its acquisition by AmerisourceBergen in February 2015. Mr. Durcan has served as a director for Advanced Micro Devices since October 2017 and for ASML Holding NV since April 2020. He previously served as a director of Veoneer from April 2018 to April 2022 and served as a director at Freescale Semiconductor, Inc. from 2014 through 2015. Mr. Durcan has been a director for St. Luke's Health System of Idaho since February 2017 and has served on the Board of Trustees of Rice University since June 2020. He has also served on the Semiconductor Industry Association Board and the Technology CEO Council.
- Richard W. Gochnauer
-
Richard W. Gochnauer自2008年9月起担任Amerisourcebergen公司董事会成员。他从2002年12月起担任联合文具社首席执行官，直至2011年5月退休，并从2002年7月至2002年12月担任联合文具社首席运营官。Gochnauer先生曾于1994年至2002年担任金州食品公司副主席兼国际总裁、总裁兼首席运营官。他目前担任金州食品公司、Vodori公司和拉什大学医学中心的董事会成员，之前曾于2011年至2020年担任UGI Corporation社区的董事，2000年至2008年担任Fieldstone Communities的董事和2002年7月至2011年5月担任United Stationers Inc.的董事。Gochnauer先生也是更高雄心领导中心的成员和SC主基金的首席主任。
Richard W. Gochnauer,has served on Cencora, Inc. Board since September 2008. He served as Chief Executive Officer of United Stationers Inc. from December 2002 until his retirement in May 2011 and as Chief Operating Officer of United Stationers Inc. from July 2002 to December 2002. Mr. Gochnauer served as Vice Chairman and President, International, and President and Chief Operating Officer of Golden State Foods Corporation from 1994 to 2002. He currently serves as a member of the Boards of Golden State Foods Corporation, Vodori Inc., and Rush University Medical Center and previously served as a director of UGI Corporation from 2011 until 2020, Fieldstone Communities, Inc. from 2000 to 2008 and United Stationers Inc. from July 2002 to May 2011. Mr. Gochnauer is also a member of the Center for Higher Ambition Leadership and Lead Director for SC Master Fund. - Richard W. Gochnauer自2008年9月起担任Amerisourcebergen公司董事会成员。他从2002年12月起担任联合文具社首席执行官，直至2011年5月退休，并从2002年7月至2002年12月担任联合文具社首席运营官。Gochnauer先生曾于1994年至2002年担任金州食品公司副主席兼国际总裁、总裁兼首席运营官。他目前担任金州食品公司、Vodori公司和拉什大学医学中心的董事会成员，之前曾于2011年至2020年担任UGI Corporation社区的董事，2000年至2008年担任Fieldstone Communities的董事和2002年7月至2011年5月担任United Stationers Inc.的董事。Gochnauer先生也是更高雄心领导中心的成员和SC主基金的首席主任。
- Richard W. Gochnauer,has served on Cencora, Inc. Board since September 2008. He served as Chief Executive Officer of United Stationers Inc. from December 2002 until his retirement in May 2011 and as Chief Operating Officer of United Stationers Inc. from July 2002 to December 2002. Mr. Gochnauer served as Vice Chairman and President, International, and President and Chief Operating Officer of Golden State Foods Corporation from 1994 to 2002. He currently serves as a member of the Boards of Golden State Foods Corporation, Vodori Inc., and Rush University Medical Center and previously served as a director of UGI Corporation from 2011 until 2020, Fieldstone Communities, Inc. from 2000 to 2008 and United Stationers Inc. from July 2002 to May 2011. Mr. Gochnauer is also a member of the Center for Higher Ambition Leadership and Lead Director for SC Master Fund.
- Steven H. Collis
-
Steven H. Collis，自2011年7月，他担任美源伯根公司的总裁将按首席执行官。2010年11月至2011年7月，他担任美源伯根公司的总裁兼首席运营官。2009年9月至2010年1月，他担任美源伯根医药公司的执行副总裁兼总裁。2007年9月至2009年9月，他担任美源伯根专业组的执行副总裁兼总裁。2001年8月至2007年9月，他担任美源伯根专业组的高级副总裁。自1994年以来，他在美源伯根公司及其前身担任很多职位。目前，他担任THORATEC公司的总监。自2001年5月，他担任么远伯根公司的总监。
Steven H. Collis,is the President and Chief Executive Officer of Cencora, Inc. and has served in this position since July 2011. He has been a member of Cencora, Inc. Board since 2011 and has served as Cencora, Inc. Board's Chairman since March 2016. From November 2010 to July 2011, Mr. Collis served as President and Chief Operating Officer of AmerisourceBergen Corporation. He served as Executive Vice President and President of AmerisourceBergen Drug Corporation from September 2009 to November 2010, as Executive Vice President and President of AmerisourceBergen Specialty Group from September 2007 to September 2009 and as Senior Vice President of AmerisourceBergen Corporation and President of AmerisourceBergen Specialty Group from August 2001 to September 2007. Mr. Collis has held a variety of other positions with Cencora and its predecessors since 1994. Mr. Collis is a member of the American Red Cross Board of Governors and the Board of International Federation of Pharmaceutical Wholesalers, Inc. He served as a member of the Board of Thoratec Corporation from 2008 to 2015 and as a member of the Board of CEOs Against Cancer (PA Chapter) from 2014 to 2019. - Steven H. Collis，自2011年7月，他担任美源伯根公司的总裁将按首席执行官。2010年11月至2011年7月，他担任美源伯根公司的总裁兼首席运营官。2009年9月至2010年1月，他担任美源伯根医药公司的执行副总裁兼总裁。2007年9月至2009年9月，他担任美源伯根专业组的执行副总裁兼总裁。2001年8月至2007年9月，他担任美源伯根专业组的高级副总裁。自1994年以来，他在美源伯根公司及其前身担任很多职位。目前，他担任THORATEC公司的总监。自2001年5月，他担任么远伯根公司的总监。
- Steven H. Collis,is the President and Chief Executive Officer of Cencora, Inc. and has served in this position since July 2011. He has been a member of Cencora, Inc. Board since 2011 and has served as Cencora, Inc. Board's Chairman since March 2016. From November 2010 to July 2011, Mr. Collis served as President and Chief Operating Officer of AmerisourceBergen Corporation. He served as Executive Vice President and President of AmerisourceBergen Drug Corporation from September 2009 to November 2010, as Executive Vice President and President of AmerisourceBergen Specialty Group from September 2007 to September 2009 and as Senior Vice President of AmerisourceBergen Corporation and President of AmerisourceBergen Specialty Group from August 2001 to September 2007. Mr. Collis has held a variety of other positions with Cencora and its predecessors since 1994. Mr. Collis is a member of the American Red Cross Board of Governors and the Board of International Federation of Pharmaceutical Wholesalers, Inc. He served as a member of the Board of Thoratec Corporation from 2008 to 2015 and as a member of the Board of CEOs Against Cancer (PA Chapter) from 2014 to 2019.
- Lon R. Greenberg
-
Lon R. Greenberg，他在UGI公司董事会他担任非执行主席，他于1996年8月担任主席，自1995年8月担任行政总裁，直到他在2013年4月退休。他1994年7月至2005年8月任前总裁，1995至1996年任董事会副主席，1989-1994年担任UGI公司法律及企业发展高级副总裁。他是坦普尔大学信托委员会成员，坦普尔大学健康系统的董事会主席。他也担任Ameriprise金融公司，AmerisourceBergen公司，UGI公用事业公司和AmeriGas Propane公司的董事。
Lon R. Greenberg,has served on Cencora, Inc. Board since May 2013. He served as Chairman of UGI Corporation's Board of Directors from 1996 until January 2016 and as director of UGI Utilities, Inc. and AmeriGas Propane, both UGI Corporation subsidiaries. Mr. Greenberg served as Chief Executive Officer of UGI Corporation from 1995 until his retirement in April 2013. Mr. Greenberg served in various leadership positions throughout his tenure with UGI Corporation. Mr. Greenberg is a member of the Board of Trustees of Temple University and the Board of Directors of The Philadelphia Foundation. He also serves as Chairman of the Board of Directors of Temple University Health System. He previously served as a member of the Boards of Aqua America, Inc. (now known as Essential Utilities, Inc.), Ameriprise Financial, Inc., Fox Chase Cancer Center and the United Way of Greater Philadelphia and Southern New Jersey. - Lon R. Greenberg，他在UGI公司董事会他担任非执行主席，他于1996年8月担任主席，自1995年8月担任行政总裁，直到他在2013年4月退休。他1994年7月至2005年8月任前总裁，1995至1996年任董事会副主席，1989-1994年担任UGI公司法律及企业发展高级副总裁。他是坦普尔大学信托委员会成员，坦普尔大学健康系统的董事会主席。他也担任Ameriprise金融公司，AmerisourceBergen公司，UGI公用事业公司和AmeriGas Propane公司的董事。
- Lon R. Greenberg,has served on Cencora, Inc. Board since May 2013. He served as Chairman of UGI Corporation's Board of Directors from 1996 until January 2016 and as director of UGI Utilities, Inc. and AmeriGas Propane, both UGI Corporation subsidiaries. Mr. Greenberg served as Chief Executive Officer of UGI Corporation from 1995 until his retirement in April 2013. Mr. Greenberg served in various leadership positions throughout his tenure with UGI Corporation. Mr. Greenberg is a member of the Board of Trustees of Temple University and the Board of Directors of The Philadelphia Foundation. He also serves as Chairman of the Board of Directors of Temple University Health System. He previously served as a member of the Boards of Aqua America, Inc. (now known as Essential Utilities, Inc.), Ameriprise Financial, Inc., Fox Chase Cancer Center and the United Way of Greater Philadelphia and Southern New Jersey.
- Kathleen Hyle
-
Kathleen Hyle于2010年5月起在Amerisourcebergen公司董事会任职。2008年11月至2012年3月，她曾担任Constellation Energy高级副总裁和Constellation Energy资源公司首席运营官。Hyle女士于2007年6月至2008年11月期间担任Constellation Energy核能集团和UniStar Nuclear Energy，LLC的Chief Financial Officer。在2003年加入Constellation Energy之前，Hyle女士曾担任ANC租赁公司Chief Financial Officer、副总裁公司兼财务主管、副总裁公司兼百得公司财务主管。她是Bunge Limited的董事会主席，也是有限责任公司WKW LLC的成员。Hyle女士是洛约拉大学马里兰塞林格商学院赞助委员会的前成员，也是马里兰州巴尔的摩非赢利剧院CenterStage董事会的前成员。
Kathleen Hyle,has served on Cencora, Inc. Board since May 2010. She served as Senior Vice President of Constellation Energy and Chief Operating Officer of Constellation Energy Resources from November 2008 until March 2012. Ms. Hyle served as Chief Financial Officer for Constellation Energy Nuclear Group and for UniStar Nuclear Energy, LLC from June 2007 to November 2008. Prior to joining Constellation Energy in 2003, Ms. Hyle served as the Chief Financial Officer of ANC Rental Corp., Vice President and Treasurer of Auto-Nation, Inc., and Vice President and Treasurer of Black & Decker Corporation. She previously served on the Board of Directors of Bunge Limited from 2012 to 2023, including as Chair from 2018 to 2023. She also serves as a member of the Board of X Energy, LLC and a member of WKW LLC. Ms. Hyle is a former member of the Board of Sponsors for the Loyola University Maryland Sellinger School of Business and Management and a former member of the Board of Trustees of CenterStage, a non-profit theatre in Baltimore, MD. - Kathleen Hyle于2010年5月起在Amerisourcebergen公司董事会任职。2008年11月至2012年3月，她曾担任Constellation Energy高级副总裁和Constellation Energy资源公司首席运营官。Hyle女士于2007年6月至2008年11月期间担任Constellation Energy核能集团和UniStar Nuclear Energy，LLC的Chief Financial Officer。在2003年加入Constellation Energy之前，Hyle女士曾担任ANC租赁公司Chief Financial Officer、副总裁公司兼财务主管、副总裁公司兼百得公司财务主管。她是Bunge Limited的董事会主席，也是有限责任公司WKW LLC的成员。Hyle女士是洛约拉大学马里兰塞林格商学院赞助委员会的前成员，也是马里兰州巴尔的摩非赢利剧院CenterStage董事会的前成员。
- Kathleen Hyle,has served on Cencora, Inc. Board since May 2010. She served as Senior Vice President of Constellation Energy and Chief Operating Officer of Constellation Energy Resources from November 2008 until March 2012. Ms. Hyle served as Chief Financial Officer for Constellation Energy Nuclear Group and for UniStar Nuclear Energy, LLC from June 2007 to November 2008. Prior to joining Constellation Energy in 2003, Ms. Hyle served as the Chief Financial Officer of ANC Rental Corp., Vice President and Treasurer of Auto-Nation, Inc., and Vice President and Treasurer of Black & Decker Corporation. She previously served on the Board of Directors of Bunge Limited from 2012 to 2023, including as Chair from 2018 to 2023. She also serves as a member of the Board of X Energy, LLC and a member of WKW LLC. Ms. Hyle is a former member of the Board of Sponsors for the Loyola University Maryland Sellinger School of Business and Management and a former member of the Board of Trustees of CenterStage, a non-profit theatre in Baltimore, MD.
高管简历
中英对照 | 中文 | 英文- Robert P. Mauch
Robert P. Mauch，一直担任执行副总裁（2015年2月以来），并于2017年6月成为集团总裁，负责药品分销与战略全球采购。从2015年2月到2017年6月，他担任AmerisourceBergen Drug Corporation的总裁。他此前曾担任AmerisourceBergen Drug Corporation的高级副总裁兼首席运营官（从2014年3月到2015年2月）。他曾担任AmerisourceBergen Drug Corporation的高级副总裁，负责运营（从2012年4月到2014年3月）。他曾担任AmerisourceBergen Drug Corporation的高级副总裁，负责销售和营销（从2011年4月到2012年4月）。他曾担任AmerisourceBergen Drug Corporation的高级副总裁，负责替代保健销售和营销（从2010年5月到2011年4月）。
Robert P. Mauch,has been Executive Vice President since February 2015 and became Chief Operating Officer in October 2022. He served as Group President from February 2019 to September 2022. He served as Group President, Pharmaceutical Distribution & Strategic Global Sourcing from June 2017 to February 2019. He served as President, AmerisourceBergen Drug Corporation from February 2015 to June 2017. Mr. Mauch served as Senior Vice President Chief Operating Officer, AmerisourceBergen Drug Corporation from March 2014 to February 2015. He was Senior Vice President, Operations, AmerisourceBergen Drug Corporation from April 2012 to March 2014. He was Senior Vice President of Sales and Marketing, AmerisourceBergen Drug Corporation from April 2011 to April 2012. He was Senior Vice President, Alternate Care Sales and Marketing, AmerisourceBergen Drug Corporation from May 2010 to April 2011. Mr. Mauch has been employed by the Company or one of its predecessors for over 25 years.- Robert P. Mauch，一直担任执行副总裁（2015年2月以来），并于2017年6月成为集团总裁，负责药品分销与战略全球采购。从2015年2月到2017年6月，他担任AmerisourceBergen Drug Corporation的总裁。他此前曾担任AmerisourceBergen Drug Corporation的高级副总裁兼首席运营官（从2014年3月到2015年2月）。他曾担任AmerisourceBergen Drug Corporation的高级副总裁，负责运营（从2012年4月到2014年3月）。他曾担任AmerisourceBergen Drug Corporation的高级副总裁，负责销售和营销（从2011年4月到2012年4月）。他曾担任AmerisourceBergen Drug Corporation的高级副总裁，负责替代保健销售和营销（从2010年5月到2011年4月）。
- Robert P. Mauch,has been Executive Vice President since February 2015 and became Chief Operating Officer in October 2022. He served as Group President from February 2019 to September 2022. He served as Group President, Pharmaceutical Distribution & Strategic Global Sourcing from June 2017 to February 2019. He served as President, AmerisourceBergen Drug Corporation from February 2015 to June 2017. Mr. Mauch served as Senior Vice President Chief Operating Officer, AmerisourceBergen Drug Corporation from March 2014 to February 2015. He was Senior Vice President, Operations, AmerisourceBergen Drug Corporation from April 2012 to March 2014. He was Senior Vice President of Sales and Marketing, AmerisourceBergen Drug Corporation from April 2011 to April 2012. He was Senior Vice President, Alternate Care Sales and Marketing, AmerisourceBergen Drug Corporation from May 2010 to April 2011. Mr. Mauch has been employed by the Company or one of its predecessors for over 25 years.
- Gina K. Clark
Gina K. Clark，2014年11月，成为Amerisourcebergen Corporation执行副总裁、首席营销官。2011年6月，她被任命为高级副总裁、首席营销官。此前，2007年1月至2011年6月，她担任AmerisourceBergen Specialty Group的营销与业务开发高级副总裁。加入AmerisourceBergen Specialty Group之前，她在Premier Inc. 、HealthSouth担任过执行领导职务，其中包括营销与联盟关系高级副总裁、关系管理部副总裁、管理式护理与全国承包高级副总裁。
Gina K. Clark,has been Executive Vice President since November 2014 and became Chief Communication & Administration Officer in June 2017. She served as Chief Marketing Officer from November 2014 to June 2017. Ms. Clark was named Senior Vice President and Chief Marketing Officer in June 2011. She previously served as Senior Vice President of Marketing and Business Development for AmerisourceBergen Specialty Group from January 2007 to June 2011. Prior to joining the Company, she worked in executive leadership roles at Premier Inc. and HealthSouth, including Senior Vice President of Marketing and Alliance Relations, Group Vice President of Relationship Management, and Senior Vice President of Managed Care and National Contracting.- Gina K. Clark，2014年11月，成为Amerisourcebergen Corporation执行副总裁、首席营销官。2011年6月，她被任命为高级副总裁、首席营销官。此前，2007年1月至2011年6月，她担任AmerisourceBergen Specialty Group的营销与业务开发高级副总裁。加入AmerisourceBergen Specialty Group之前，她在Premier Inc. 、HealthSouth担任过执行领导职务，其中包括营销与联盟关系高级副总裁、关系管理部副总裁、管理式护理与全国承包高级副总裁。
- Gina K. Clark,has been Executive Vice President since November 2014 and became Chief Communication & Administration Officer in June 2017. She served as Chief Marketing Officer from November 2014 to June 2017. Ms. Clark was named Senior Vice President and Chief Marketing Officer in June 2011. She previously served as Senior Vice President of Marketing and Business Development for AmerisourceBergen Specialty Group from January 2007 to June 2011. Prior to joining the Company, she worked in executive leadership roles at Premier Inc. and HealthSouth, including Senior Vice President of Marketing and Alliance Relations, Group Vice President of Relationship Management, and Senior Vice President of Managed Care and National Contracting.
- Lazarus Krikorian
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Silvana Battaglia
Silvana Battaglia自2019年1月以来一直担任执行副总裁兼首席人力资源官。在加入公司之前，她于2017年8月至2018年12月在Aramark担任全球薪酬，福利和劳资关系高级副总裁以及高级副总裁。于2011年5月至2017年8月担任全球现场人力资源总监。她还曾在Day＆Zimmerman和Merck Corporation工作。
Silvana Battaglia,has been Executive Vice President and Chief Human Resources Officer since January 2019. Prior to joining the Company, she worked at Aramark as Senior Vice President of Global Compensation, Benefits, and Labor Relations from August 2017 to December 2018 and as Senior Vice President, Global Field Human Resources from May 2011 to August 2017. She also previously worked for Day & Zimmerman and Merck Corporation.- Silvana Battaglia自2019年1月以来一直担任执行副总裁兼首席人力资源官。在加入公司之前，她于2017年8月至2018年12月在Aramark担任全球薪酬，福利和劳资关系高级副总裁以及高级副总裁。于2011年5月至2017年8月担任全球现场人力资源总监。她还曾在Day＆Zimmerman和Merck Corporation工作。
- Silvana Battaglia,has been Executive Vice President and Chief Human Resources Officer since January 2019. Prior to joining the Company, she worked at Aramark as Senior Vice President of Global Compensation, Benefits, and Labor Relations from August 2017 to December 2018 and as Senior Vice President, Global Field Human Resources from May 2011 to August 2017. She also previously worked for Day & Zimmerman and Merck Corporation.
- Leslie E. Donato
Leslie E. Donato自2019年7月起担任执行副总裁兼首席战略官。在加入公司之前，她于2009年5月至2019年5月在拜耳担任过各种领导职务，包括战略副总裁，药品部，战略副总裁，美国拜耳医疗保健公司，神经病学和血液学副总裁兼总经理。她还曾在麦肯锡公司（McKinsey＆Company）任职医疗保健业务合伙人。
Leslie E. Donato,has been Executive Vice President and Chief Strategy Officer since July 2019. Prior to joining the Company, she held various leadership roles at Bayer from May 2009 to May 2019, including Vice President of Strategy, Pharmaceuticals Division, Vice President of Strategy, Bayer Healthcare US, and Vice President & General Manager of Neurology & Hematology. She also worked for McKinsey & Company where she was a Partner in the Healthcare Practice.- Leslie E. Donato自2019年7月起担任执行副总裁兼首席战略官。在加入公司之前，她于2009年5月至2019年5月在拜耳担任过各种领导职务，包括战略副总裁，药品部，战略副总裁，美国拜耳医疗保健公司，神经病学和血液学副总裁兼总经理。她还曾在麦肯锡公司（McKinsey＆Company）任职医疗保健业务合伙人。
- Leslie E. Donato,has been Executive Vice President and Chief Strategy Officer since July 2019. Prior to joining the Company, she held various leadership roles at Bayer from May 2009 to May 2019, including Vice President of Strategy, Pharmaceuticals Division, Vice President of Strategy, Bayer Healthcare US, and Vice President & General Manager of Neurology & Hematology. She also worked for McKinsey & Company where she was a Partner in the Healthcare Practice.
- Elizabeth S. Campbell
Elizabeth S. Campbell于2021年9月被任命为Amerisourcebergen Corporation执行副总裁兼首席法律官。她于2020年6月至2021年8月担任高级副总裁和副总法律顾问。在此之前，Campbell女士曾在Amerisourcebergen Corporation法律部门担任各种职务，并承担更多责任，包括担任首席诉讼人和首席合规顾问。
Elizabeth S. Campbell,has been Executive Vice President and Chief Legal Officer since September 2021. She served as Senior Vice President and Deputy General Counsel from June 2020 to August 2021. Prior to that, Ms. Campbell served in a variety of roles within the Company's legal department with increased responsibility, including serving as Chief Litigator and Chief Compliance Counsel. Ms. Campbell has been employed by the Company for 13 years.- Elizabeth S. Campbell于2021年9月被任命为Amerisourcebergen Corporation执行副总裁兼首席法律官。她于2020年6月至2021年8月担任高级副总裁和副总法律顾问。在此之前，Campbell女士曾在Amerisourcebergen Corporation法律部门担任各种职务，并承担更多责任，包括担任首席诉讼人和首席合规顾问。
- Elizabeth S. Campbell,has been Executive Vice President and Chief Legal Officer since September 2021. She served as Senior Vice President and Deputy General Counsel from June 2020 to August 2021. Prior to that, Ms. Campbell served in a variety of roles within the Company's legal department with increased responsibility, including serving as Chief Litigator and Chief Compliance Counsel. Ms. Campbell has been employed by the Company for 13 years.
- James F. Cleary, Jr.
James F. Cleary, Jr.自2015年3月起担任执行副总裁，并于2018年11月成为Chief Financial Officer。2017年6月至2018年11月，他担任全球商业化服务和动物保健集团总裁。他曾于2015年3月至2017年6月担任MWI Animal Health总裁。在加入公司之前，他从2002年6月起担任MWI Veterinary Supply，Inc.的总裁兼首席执行官。
James F. Cleary, Jr.,has been Executive Vice President since March 2015 and became Chief Financial Officer in November 2018. He served as Group President, Global Commercialization Services & Animal Health from June 2017 to November 2018. He previously served as President, MWI Animal Health from March 2015 to June 2017. Prior to joining the Company, he was President and Chief Executive Officer of MWI Veterinary Supply, Inc. from June 2002. Mr. Cleary has been employed by the Company or one of its predecessors for over 25 years.- James F. Cleary, Jr.自2015年3月起担任执行副总裁，并于2018年11月成为Chief Financial Officer。2017年6月至2018年11月，他担任全球商业化服务和动物保健集团总裁。他曾于2015年3月至2017年6月担任MWI Animal Health总裁。在加入公司之前，他从2002年6月起担任MWI Veterinary Supply，Inc.的总裁兼首席执行官。
- James F. Cleary, Jr.,has been Executive Vice President since March 2015 and became Chief Financial Officer in November 2018. He served as Group President, Global Commercialization Services & Animal Health from June 2017 to November 2018. He previously served as President, MWI Animal Health from March 2015 to June 2017. Prior to joining the Company, he was President and Chief Executive Officer of MWI Veterinary Supply, Inc. from June 2002. Mr. Cleary has been employed by the Company or one of its predecessors for over 25 years.
- Steven H. Collis
Steven H. Collis，自2011年7月，他担任美源伯根公司的总裁将按首席执行官。2010年11月至2011年7月，他担任美源伯根公司的总裁兼首席运营官。2009年9月至2010年1月，他担任美源伯根医药公司的执行副总裁兼总裁。2007年9月至2009年9月，他担任美源伯根专业组的执行副总裁兼总裁。2001年8月至2007年9月，他担任美源伯根专业组的高级副总裁。自1994年以来，他在美源伯根公司及其前身担任很多职位。目前，他担任THORATEC公司的总监。自2001年5月，他担任么远伯根公司的总监。
Steven H. Collis,is the President and Chief Executive Officer of Cencora, Inc. and has served in this position since July 2011. He has been a member of Cencora, Inc. Board since 2011 and has served as Cencora, Inc. Board's Chairman since March 2016. From November 2010 to July 2011, Mr. Collis served as President and Chief Operating Officer of AmerisourceBergen Corporation. He served as Executive Vice President and President of AmerisourceBergen Drug Corporation from September 2009 to November 2010, as Executive Vice President and President of AmerisourceBergen Specialty Group from September 2007 to September 2009 and as Senior Vice President of AmerisourceBergen Corporation and President of AmerisourceBergen Specialty Group from August 2001 to September 2007. Mr. Collis has held a variety of other positions with Cencora and its predecessors since 1994. Mr. Collis is a member of the American Red Cross Board of Governors and the Board of International Federation of Pharmaceutical Wholesalers, Inc. He served as a member of the Board of Thoratec Corporation from 2008 to 2015 and as a member of the Board of CEOs Against Cancer (PA Chapter) from 2014 to 2019.- Steven H. Collis，自2011年7月，他担任美源伯根公司的总裁将按首席执行官。2010年11月至2011年7月，他担任美源伯根公司的总裁兼首席运营官。2009年9月至2010年1月，他担任美源伯根医药公司的执行副总裁兼总裁。2007年9月至2009年9月，他担任美源伯根专业组的执行副总裁兼总裁。2001年8月至2007年9月，他担任美源伯根专业组的高级副总裁。自1994年以来，他在美源伯根公司及其前身担任很多职位。目前，他担任THORATEC公司的总监。自2001年5月，他担任么远伯根公司的总监。
- Steven H. Collis,is the President and Chief Executive Officer of Cencora, Inc. and has served in this position since July 2011. He has been a member of Cencora, Inc. Board since 2011 and has served as Cencora, Inc. Board's Chairman since March 2016. From November 2010 to July 2011, Mr. Collis served as President and Chief Operating Officer of AmerisourceBergen Corporation. He served as Executive Vice President and President of AmerisourceBergen Drug Corporation from September 2009 to November 2010, as Executive Vice President and President of AmerisourceBergen Specialty Group from September 2007 to September 2009 and as Senior Vice President of AmerisourceBergen Corporation and President of AmerisourceBergen Specialty Group from August 2001 to September 2007. Mr. Collis has held a variety of other positions with Cencora and its predecessors since 1994. Mr. Collis is a member of the American Red Cross Board of Governors and the Board of International Federation of Pharmaceutical Wholesalers, Inc. He served as a member of the Board of Thoratec Corporation from 2008 to 2015 and as a member of the Board of CEOs Against Cancer (PA Chapter) from 2014 to 2019.